A Research of Application of the New Model of Standardized Secondary Prevention of Stroke

To promote the application of the standardized secondary prevention of stroke in primary hospitals,and further reduce the recurrence rate, disability rate, and socioeconomic burden in China, the investigators aim to popularize the standard secondary stroke prevention strategy through artificial intelligence technology, and thus to establish an information management system for standard treatment of stroke.

Inclusion Criteria:First clinical onset or previous cerebral infarction without serious sequela (mRS is 0-2 points)Age ≥ 18 years oldPatients or family members own and use smart phonesInformed consent signed by the patient or his/her legal representativeExclusion Criteria:Cranial CT confirmed intracranial hemorrhagic diseases (cerebral hemorrhage, subarachnoid hemorrhage) or malignant space occupying lesionsTransient ischemic attack, or stroke mimicCerebral embolism or suspected cerebral embolism, or other clear anticoagulant indications (such as DVT)Severe disturbance of consciousness: GCS≤8Dysphagia; or gastrointestinal disease or gastrointestinal surgery may affect gastrointestinal absorptionAfter the onset of thrombolysis, stent surgery, or will carry out arteriovenous thrombolysis, interventional or stent surgery patientsAngioplasty or other operations that need to suspend antiplatelet drugs may be performed in the last 3 monthsPatients with severe heart, lung and kidney dysfunction (creatinine > 2.0 mg/dL or 177 /μ mol/L), severe liver damage (alanine aminotransferase/aspartate transaminas，ALT/AST>1.5×ULN), malignant tumor, etc., with life expectancy less than 3 monthsPatients with hemorrhagic tendency, laboratory examination: international normalized ratio （INR）> 1.5 or activated partial thromboplastin time（APTT） > 2 times or platelet （PLT ）< 100×10^9 / LPatients with previous allergy or intolerance to clopidogrel and aspirinPregnant or lactating womenPatients who could not be followed up as required during the study periodWithout pariticipation in other intervention clinical studies in the last three months